Therapeutic Antibodies
Subscribe to
our newsletters!
Showing 21–28 of 28 resultsSorted by latest
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
-
April of 2024Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023Original price was: € 2150.00.€ 1720.00Current price is: € 1720.00.
-
July of 2023This report provides a competitor evaluation in the field of antibodies, proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor€ 400.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.
-
May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00